ID

22331

Description

A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD) Medicine: rosiglitazone, Condition: Alzheimer's Disease, Phase: 2, Clinical Study ID: 49653/461, This form is to be performed in Treatment Phase. Sponsor: GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Lien

https://clinicaltrials.gov/ct2/show/NCT00265148?term=NCT00265148&rank=1

Mots-clés

Versions (1)
  1. 30/05/2017 30/05/2017 -
Téléchargé le

30 mai 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

Anglais

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 Formulaires  
Concomitant Medication
Description

Concomitant Medication

Alias
UMLS CUI-1
C2347852
Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
Description

Concomitant agent

Type de données

boolean

Alias
UMLS CUI [1]
C2347852
Concomitant Medication Changes
Description

Concomitant Medication Changes

Alias
UMLS CUI-1
C2347852
Drug name (Trade Name preferred)
Description

Drug name

Type de données

text

Alias
UMLS CUI [1]
C0013227
SINGLE Dose/ Unit (e.g. 500mg)
Description

Single dose/Unit

Type de données

float

Alias
UMLS CUI [1,1]
C2826257
UMLS CUI [1,2]
C1960417
Frequency of this Dose (e.g. BID PRN)
Description

Frequency

Type de données

text

Alias
UMLS CUI [1]
C3476109
Route
Description

Concomitant Medication Route of Administration

Type de données

text

Alias
UMLS CUI [1]
C2826730
Indication
Description

Indication

Type de données

text

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C3146298
Start Date/Time
Description

Start Date Time

Type de données

datetime

Alias
UMLS CUI [1]
C2827019
End Date/Time
Description

Stop Date

Type de données

datetime

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C1522314
Continuing at end of Study?
Description

Continuing at end of study

Type de données

boolean

Alias
UMLS CUI [1]
C1553904
Retour au début de la page

Similar models

Concomitant Medication Effects of Rosiglitazone on Cerebral Glucose Utilization and Cognition in Subjects With Alzheimer's Disease NCT00265148

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Concomitant Medication
C2347852 (UMLS CUI-1)
Concomitant agent
Item
Are there any concomitant medication CHANGES since the start of the study? If "YES", please record all medications below. Where appropriate, medical conditions should be recorded on the Adverse Events Form, utilizing the same terminology. If a medication has had a dosage change it must be recorded with the start and stop date.
boolean
C2347852 (UMLS CUI [1])
Item Group
Concomitant Medication Changes
C2347852 (UMLS CUI-1)
Drug name
Item
Drug name (Trade Name preferred)
text
C0013227 (UMLS CUI [1])
Single dose/Unit
Item
SINGLE Dose/ Unit (e.g. 500mg)
float
C2826257 (UMLS CUI [1,1])
C1960417 (UMLS CUI [1,2])
Frequency
Item
Frequency of this Dose (e.g. BID PRN)
text
C3476109 (UMLS CUI [1])
Concomitant Medication Route of Administration
Item
Route
text
C2826730 (UMLS CUI [1])
Indication
Item
Indication
text
C2347852 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
Start Date Time
Item
Start Date/Time
datetime
C2827019 (UMLS CUI [1])
Stop Date
Item
End Date/Time
datetime
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
C0013227 (UMLS CUI [2,1])
C1522314 (UMLS CUI [2,2])
Continuing at end of study
Item
Continuing at end of Study?
boolean
C1553904 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial